Elanco Animal Health (NYSE:ELAN) Sets New 52-Week High - Should You Buy?

Key Points

• Elanco Animal Health's stock reached a new 52-week high of $21.78, with a last trading price of $21.59.
• Analyst upgrades have significantly changed the ratings, with William Blair moving to an "outperform" rating and JPMorgan Chase raising the price target from $18.00 to $24.00.
• The company reported impressive quarterly earnings, with an EPS of $0.26 surpassing estimates, and a year-over-year revenue increase of 4.8%.

Elanco Animal Health Incorporated (NYSE:ELAN - Get Free Report)'s share price hit a new 52-week high on Monday . The stock traded as high as $21.78 and last traded at $21.59, with a volume of 240311 shares. The stock had previously closed at $21.42.

Analyst Ratings Changes

A number of equities research analysts have issued reports on ELAN shares. William Blair upgraded Elanco Animal Health from a "market perform" rating to an "outperform" rating in a research report on Thursday, June 26th. Weiss Ratings reissued a "hold (c-)" rating on shares of Elanco Animal Health in a research report on Wednesday, October 8th. Leerink Partnrs raised shares of Elanco Animal Health from a "hold" rating to a "strong-buy" rating in a research note on Thursday, July 17th. JPMorgan Chase & Co. raised shares of Elanco Animal Health from a "neutral" rating to an "overweight" rating and increased their target price for the company from $18.00 to $24.00 in a research note on Tuesday, October 7th. Finally, Stifel Nicolaus increased their price objective on shares of Elanco Animal Health from $18.00 to $23.00 and gave the stock a "buy" rating in a research report on Wednesday, September 24th. Two analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and three have given a Hold rating to the company's stock. Based on data from MarketBeat.com, Elanco Animal Health presently has a consensus rating of "Moderate Buy" and an average target price of $19.14.

Elanco Animal Health Stock Performance

The firm has a market cap of $10.75 billion, a PE ratio of 25.17, a PEG ratio of 3.93 and a beta of 1.65. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.40 and a current ratio of 2.60. The firm's 50 day moving average price is $18.90 and its two-hundred day moving average price is $14.81.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported $0.26 EPS for the quarter, beating analysts' consensus estimates of $0.20 by $0.06. The company had revenue of $1.24 billion for the quarter, compared to the consensus estimate of $1.19 billion. Elanco Animal Health had a return on equity of 7.04% and a net margin of 9.68%.The company's revenue for the quarter was up 4.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.30 earnings per share. Elanco Animal Health has set its Q3 2025 guidance at 0.120-0.160 EPS. FY 2025 guidance at 0.850-0.91 EPS. On average, research analysts forecast that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current year.

Hedge Funds Weigh In On Elanco Animal Health

A number of institutional investors and hedge funds have recently modified their holdings of the company. Allworth Financial LP grew its holdings in shares of Elanco Animal Health by 791.7% during the first quarter. Allworth Financial LP now owns 2,354 shares of the company's stock worth $25,000 after purchasing an additional 2,090 shares during the last quarter. Farther Finance Advisors LLC raised its holdings in Elanco Animal Health by 79.3% during the third quarter. Farther Finance Advisors LLC now owns 2,151 shares of the company's stock worth $43,000 after purchasing an additional 951 shares in the last quarter. First Horizon Advisors Inc. grew its position in Elanco Animal Health by 184.3% during the second quarter. First Horizon Advisors Inc. now owns 3,724 shares of the company's stock worth $53,000 after buying an additional 2,414 shares during the period. Wealthquest Corp purchased a new position in shares of Elanco Animal Health during the 1st quarter worth approximately $56,000. Finally, Caitong International Asset Management Co. Ltd boosted its stake in shares of Elanco Animal Health by 261.6% during the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 4,039 shares of the company's stock worth $58,000 after purchasing an additional 2,922 shares during the last quarter. Institutional investors and hedge funds own 97.48% of the company's stock.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.